NovoCure Reports Record Q3 2026 Revenue and First Positive Adjusted EBITDA in Four Years
NovoCure (NVCR) reported strong third-quarter 2026 financial results, highlighted by a 16% year-over-year increase in net revenue to $193.4 million. A key milestone was achieved as the company posted its first positive adjusted EBITDA of $15.7 million in over four years, signaling a potential shift toward long-term profitability. Growth was primarily driven by a 19% rise in global active patients, totaling 5,260. The company raised its full-year 2026 revenue guidance to a range of $736 million to $743 million and increased its adjusted EBITDA forecast significantly. While the Optune Lua expansion in Japan showed strong momentum, CEO Frank Leonard noted administrative challenges regarding the Optune Pax launch in the U.S., specifically involving insurance appeals and clinical management issues. Despite these headwinds, NovoCure maintains a robust liquidity position with $463.5 million in cash and investments.
Tickers: $NVCR
Topics: EBITDA profitability guidance raise patient metrics revenue growth